Oculis Holding AG (NASDAQ:OCS) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Oculis Holding AG (NASDAQ:OCS) has earned an average rating of “Moderate Buy” from the nine research firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $49.3750.

OCS has been the topic of several research analyst reports. JPMorgan Chase & Co. boosted their price target on Oculis from $38.00 to $42.00 and gave the company an “overweight” rating in a research note on Monday, May 18th. Needham & Company LLC boosted their price objective on Oculis from $40.00 to $46.00 and gave the company a “buy” rating in a report on Tuesday, May 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Oculis in a report on Tuesday, April 21st. HC Wainwright boosted their price objective on Oculis from $44.00 to $47.00 and gave the company a “buy” rating in a report on Tuesday, May 12th. Finally, Wall Street Zen cut Oculis from a “hold” rating to a “sell” rating in a report on Saturday, March 7th.

Oculis Trading Down 4.9%

Shares of NASDAQ OCS opened at $29.49 on Friday. The firm has a market cap of $1.71 billion, a PE ratio of -13.85 and a beta of 0.38. The company has a quick ratio of 5.18, a current ratio of 5.18 and a debt-to-equity ratio of 0.01. Oculis has a twelve month low of $16.00 and a twelve month high of $34.47. The business has a fifty day simple moving average of $27.48 and a two-hundred day simple moving average of $24.86.

Oculis (NASDAQ:OCS) last announced its earnings results on Monday, May 11th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.14). The business had revenue of $0.26 million for the quarter, compared to analysts’ expectations of $0.25 million. Oculis had a negative return on equity of 56.78% and a negative net margin of 8,460.67%. Analysts expect that Oculis will post -2.21 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Oculis

Large investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. raised its holdings in Oculis by 100.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock worth $40,000 after purchasing an additional 1,000 shares during the period. Aventura Private Wealth LLC acquired a new position in Oculis in the 4th quarter worth about $80,000. Koshinski Asset Management Inc. acquired a new position in Oculis in the 1st quarter worth about $238,000. Millennium Management LLC acquired a new position in Oculis in the 4th quarter worth about $312,000. Finally, Himension Capital Singapore PTE. LTD. acquired a new position in Oculis in the 1st quarter worth about $503,000. Institutional investors and hedge funds own 22.30% of the company’s stock.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.